Details for New Drug Application (NDA): 202161
✉ Email this page to a colleague
NDA 202161 describes DESONIDE, which is a drug marketed by Alembic, Cadila, Cosette, Glenmark Speclt, Padagis Us, Taro, Cintex Svcs, Fougera Pharms, Pai Holdings Pharm, Encube Ethicals, Glenmark Pharms Ltd, and Hikma, and is included in twenty NDAs. It is available from fourteen suppliers. Additional details are available on the DESONIDE profile page.
The generic ingredient in DESONIDE is desonide. There are thirty-one drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the desonide profile page.
The generic ingredient in DESONIDE is desonide. There are thirty-one drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the desonide profile page.
Pharmacology for NDA: 202161
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 202161
Suppliers and Packaging for NDA: 202161
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DESONIDE | desonide | LOTION;TOPICAL | 202161 | ANDA | Taro Pharmaceuticals U.S.A., Inc. | 51672-4079 | 51672-4079-4 | 1 BOTTLE in 1 CARTON (51672-4079-4) / 59 mL in 1 BOTTLE |
| DESONIDE | desonide | LOTION;TOPICAL | 202161 | ANDA | Taro Pharmaceuticals U.S.A., Inc. | 51672-4079 | 51672-4079-8 | 1 BOTTLE in 1 CARTON (51672-4079-8) / 118 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | LOTION;TOPICAL | Strength | 0.05% | ||||
| Approval Date: | Oct 31, 2014 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
